The 66th American Society of Hematology (ASH) Annual Meeting & Exposition took place December 7-10, 2024, in San Diego, California; the 2025 meeting is currently scheduled to take place in Orlando ...

At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...

During the 66th Annual Meeting of the American Society of Hematology (ASH) held in San Diego from December 7 to 10, ...

Laboratory studies uncover a simple yet promising approach to enhance personalized cell therapy. A dietary supplement may ...

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...

Hematology Oncology of Indiana Physician Research Presented at 66th ASH Annual Meeting ...

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

A study presented at the American Society of Hematology (ASH) annual meeting revealed that multiple myeloma patients with higher socioeconomic deprivation, as measured by the Area Deprivation Index ...

In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases ...

CD19-positive B-cell malignancies at the 2024 American Society of Hematology (ASH) Annual Meeting. Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) granted ...

A pair of assessments conducted by the American Society of Hematology (ASH) have helped identify roadblocks to improving diversity in clinical trials and elucidated the strategies ASH members use ...